Dapagliflozin is an SGLT2 inhibitor indicated for diabetes, heart failure, and chronic kidney disease. Proven cardiorenal effect.
Also known as: Farxiga, Forxiga
No documented drug–drug interactions for this medicine.
No documented food or drink interactions.
Reduces HF hospitalisation (DAPA-HF trial). Consider in HF with or without T2DM.
Start 10 mg/day. Benefit independent of glycaemic control.
DailyMed/FDA (NIH/NLM) — approved Dapagliflozin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69
CONTRAINDICATED in pregnancy. Risk of fetal renal harm.
CONTRAINDICATED in 2nd and 3rd trimesters.
Unknown if excreted in breast milk.
Discontinue before conception.
DailyMed/FDA (NIH/NLM) — approved Dapagliflozin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Selectively inhibits SGLT2, blocking renal glucose reabsorption and promoting glycosuria.
Blocks SGLT2 in the proximal tubule, preventing glucose transport. Excreted glucose drags sodium and water (osmotic diuretic).
Oral bioavailability: 78%. Food does not affect absorption. Tmax: 1-2 hours.
Metabolised by UGT1A6, UGT1A9 to inactive glucuronide (M2 metabolite). M3 metabolite (4-hydroxyl) with reduced activity. Does not interfere with CYP.
12.9 hours. Elimination: ~75% urine (metabolites), ~20% faeces.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
